Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Acute myeloid leukemia | R-HSA-9680350 | map05221 | mephenesin | 4059 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | mephenesin | 4059 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | nitrofurantoin | 4417 | drug-path |
| Complement and coagulation cascades | R-HSA-114591 | map04610 | nitrofurantoin | 4417 | drug-path |
| Regulation of actin cytoskeleton | R-HSA-392751 | map04810 | nitrofurantoin | 4417 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | nitrofurantoin | 4417 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | ofloxacin | 2562 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | ofloxacin | 2562 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | ofloxacin | 2562 | drug-path |
| Asthma | R-HSA-444620 | map05310 | ofloxacin | 2562 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | ofloxacin | 2562 | drug-path |
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | ofloxacin | 2562 | drug-path |
| Phosphatidylinositol signaling system | R-HSA-1280215 | map04070 | ofloxacin | 2562 | drug-path |
| Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | ofloxacin | 2562 | drug-path |
| Autoimmune thyroid disease | R-HSA-1643685 | map05320 | ofloxacin | 2562 | drug-path |
| Antigen processing and presentation | R-HSA-1236975 | map04612 | ofloxacin | 2562 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | ofloxacin | 2562 | drug-path |
| Gap junction | R-HSA-190861 | map04540 | ofloxacin | 2562 | drug-path |
| ABC transporters | R-HSA-1369007 | map02010 | clemizole | 1548955 | drug-path |
| Alzheimer's disease | R-HSA-1643685 | 0 | clemizole | 1548955 | drug-path |